-
公开(公告)号：KR1020080096026A
公开(公告)日：2008-10-30
申请号：KR1020070040859
申请日：2007-04-26
Applicant: (주)아모레퍼시픽 , 동국대학교 산학협력단
CPC classification number: C12Q1/6834 , G01N33/563
Abstract: A kit for predicting chloasma is provided to predict rapidly and sensitively potentialities of forming chloasma from skin by 23 kinds of genes highly revealed and 5 kinds of genes lowly revealed near the chloasma region. A kit for predicting chloasma comprises one or more monoclonal antibodies having the amino acid sequence coded by a gene selected from a group consisting of PCOLCE2, GFPT2, CCL21, WIF1 and H19 as a variable region. If an amount of the antigen combined in the antibody is less than a normal value, it is diagnose as the skin in which the chloasma is easily formed.
Abstract translation: 提供了一种用于预测黄褐斑的试剂盒，用于预测23种高度显示的基因和5种在黄褐斑区域附近低度显露的基因，从而快速灵敏地形成皮肤形成黄褐斑的潜力。 用于预测黄褐斑的试剂盒包含一种或多种具有由选自由PCOLCE2，GFPT2，CCL21，WIF1和H19组成的组的基因编码的氨基酸序列作为可变区的单克隆抗体。 如果抗体中组合的抗原量少于正常值，则诊断为容易形成黄褐斑的皮肤。
-
公开(公告)号：KR100788241B1
公开(公告)日：2007-12-27
申请号：KR1020070006652
申请日：2007-01-22
Applicant: 동국대학교 산학협력단
IPC: C12Q1/00
CPC classification number: G01N33/5044 , G01N2500/00
Abstract: A method for screening a material for preventing or treating leukoplakia is provided to screen a prophylactic or a therapeutic agent of the leukoplakia in a high-throughput manner. A method for screening a material for preventing or treating leukoplakia comprises the steps of: (a) isolating epidermal cells of the leukoplakia and culturing them; (b) contacting candidate materials for preventing or treating the leukoplakia with the cultured epidermal cells; (c) measuring phosphorylation of I-kappaB, NF-kappaB, Akt or IKK from the candidate materials-contacted cells; and (d) selecting the candidate materials increasing the phosphorylation of I-kappaB, NF-kappaB, Akt or IKK.
Abstract translation: 提供筛选用于预防或治疗白斑病的材料的方法，以高通量方式筛选白斑病的预防或治疗剂。 用于筛选预防或治疗白斑病的材料的方法包括以下步骤：（a）分离白斑的表皮细胞并培养它们; （b）接触用于预防或治疗白斑的候选材料与培养的表皮细胞; （c）从候选材料接触细胞测量I-kappaB，NF-κB，Akt或IKK的磷酸化; 和（d）选择增加I-kappaB，NF-kappaB，Akt或IKK磷酸化的候选物质。
-
公开(公告)号：KR102116449B1
公开(公告)日：2020-05-29
申请号：KR1020180117046
申请日：2018-10-01
Applicant: 동국대학교 산학협력단
IPC: C12Q1/6883 , G01N33/50 , G01N33/68
-
14.发明公开
公开(公告)号：KR1020150119741A
公开(公告)日：2015-10-26
申请号：KR1020140045547
申请日：2014-04-16
Applicant: (주)아모레퍼시픽 , 동국대학교 산학협력단
IPC: A61K48/00 , A61K39/395 , A61K8/96 , A61P17/00 , A61Q19/02
CPC classification number: C07K16/28 , A61K2039/505 , C07K16/2896
Abstract: 본발명은캐드헤린11(Cadherin 11) 및 N-캐드헤린(N-cadherin) 중하나이상의발현억제물질을유효성분으로포함하는피부개선용조성물및 이를포함하는피부개선키트를제공함으로써피부과색소침착증을개선할수 있으며, 피부미백효과를제공할수 있다. 피부주름생성을방지또는완화할수 있으므로, 우수한항노화효과를제공한다. 또한, 본발명은섬유아세포(fibroblast), 각질형성세포(keratinocyte) 및멜라닌생성세포(melanocyte) 중 2종이상의공배양물을포함하는피부개선물질스크리닝시스템, 및상기피부개선물질스크리닝시스템의공배양물에후보물질을처리하는단계, 및캐드헤린11 및 N-캐드헤린중 하나이상의발현변화를측정하는단계를포함하는것을특징으로하는피부개선물질의스크리닝방법을제공함으로써, 생체외(in vitro)에서도임상적으로캐드헤린11, N-캐드헤린의발현변화를용이하게측정하여, 피부개선물질을효과적으로스크리닝할수 있다.
Abstract translation: 本发明提供一种皮肤改善组合物，其包含抑制钙粘蛋白11和N-钙粘蛋白中的至少一种的表达的作为活性物质的材料，以及包含其的皮肤改善剂。 根据本发明，可以减轻皮肤色素沉着过度; 可以提供皮肤美白效果; 并且由于皮肤改善组合物可以防止或减轻皱纹的产生，因此可以提供优异的抗老化效果。 本发明提供了一种用于筛选皮肤改善材料的系统，其包括来自成纤维细胞，角质形成细胞和黑素细胞的至少两种的共培养产物，以及用于筛选皮肤改善材料的方法。 该方法包括以下步骤：用候选材料处理系统的共培养产物以筛选皮肤改善材料; 并测定钙粘蛋白11和N-钙粘蛋白中至少一种的表达变化。 钙粘蛋白11和N-钙粘蛋白中至少一种的表达变化可以在体外和容易的方式进行临床测定。 因此，可以有效地筛选皮肤改善材料。
-
Patent Agency Ranking
公开(公告)号：KR101362951B1
公开(公告)日：2014-02-28
申请号：KR1020070040859
申请日：2007-04-26
Applicant: (주)아모레퍼시픽 , 동국대학교 산학협력단
Abstract: 본 발명은 기미 형성 예지방법 및 기미 형성 예지용 진단 키트에 관한 것으로서, 구체적으로는 기미 조직과 정상피부 조직 간에 다르게 발현되는 유전자들의 발현량을 확인하여 피부의 기미 형성 가능성을 진단하기 위하여, 상기 유전자 서열의 폴리뉴클레오티드와 혼성화하는 프로브로서 하나 이상의 폴리뉴클레오티드 또는 그의 상보적 폴리뉴클레오티드; 상기 유전자 서열의 폴리뉴클레오티드의 프라이머 쌍; 또는 상기 유전자에 의하여 코딩되는 아미노산 서열을 가변영역으로 가지는 하나 이상의 모노클로날 항체를 포함하는 기미 형성 예지방법 및 진단 키트에 관한 것이다. 본 발명에 따르면 기미 병변 부위에서 특이적으로 고발현되는 23종의 유전자 및 5종의 저발현 유전자를 기미 마커 유전자로 하여 피부에서의 기미 형성 가능성을 민감하고 빠르게 진단할 수 있다.
기미, 키트, 고발현, 저발현Abstract translation: 到本发明涉及一种用于该方法的预后色斑的形成和色斑的形成预测的诊断试剂盒，具体地，以确定要在染色的组织和正常皮肤组织之间差异表达来诊断形成在皮肤上的斑点的可能性的基因的表达水平，该基因 作为与该序列的多核苷酸杂交的探针的一个或多个多核苷酸或其互补多核苷酸; 该基因序列的多核苷酸的引物对; 或者至少一种具有由该基因编码的氨基酸序列作为可变区的单克隆抗体。 根据本发明可能会受到特定的基因和其在患处被表达染色斑点的标记基因，是在皮肤上形成，并迅速诊断斑点的可能性敏感的23个基因和5种的表达。
-
公开(公告)号：KR1020140014031A
公开(公告)日：2014-02-05
申请号：KR1020130144072
申请日：2013-11-25
Applicant: (주)아모레퍼시픽 , 동국대학교 산학협력단
IPC: C12Q1/68 , G01N33/68 , G01N33/563 , C12N15/11
CPC classification number: C12Q1/6883 , C12Q1/6837 , C12Q2525/204 , C12Q2600/136 , C12Q2600/158 , G01N33/54306 , G01N33/6893 , G01N2500/00
Abstract: The present invention relates to a method and a kit for predicting chloasma. More specifically, in order to diagnose possibility of forming the chloasma by checking expression amount of genes which are differently expressed between chloasma tissues and normal skin tissues, a method and a kit for predicting chloasma comprise: one or more polynucleotides or complementary polynucleotides as probes which hybridize with polynucleotides of the sequence of the genes; a pair of polynucleotide primers of the sequence of the genes; or one or more monoclonal antibodies having amino acid sequences coded by the genes as a variable region. According to the present invention, the possibility of forming the chloasma on skin can be sensitively and rapidly diagnosed by using 23 kinds of highly expressed genes and 5 kinds of down regulated genes, which are specific to chloasma lesion area, as chloasma marker genes. [Reference numerals] (AA) Relative mRNA expression amount in melasma regions compare to normal region; (BB) Normal region
Abstract translation: 本发明涉及一种用于预测黄褐斑的方法和试剂盒。 更具体地，为了通过检查在黄褐斑组织和正常皮肤组织之间不同表达的基因的表达量来诊断形成黄褐斑的可能性，用于预测黄褐斑的方法和试剂盒包括：一个或多个多核苷酸或互补多核苷酸作为探针， 与基因序列的多核苷酸杂交; 基因序列的一对多核苷酸引物; 或具有由该基因编码的氨基酸序列作为可变区的一种或多种单克隆抗体。 根据本发明，通过使用23种高度表达的基因和对黄褐斑病变区域特异性的5种下调基因作为黄褐斑标记基因，可以敏感地和快速地诊断形成皮肤上的黄褐斑的可能性。 （AA）与正常区相比，黑斑病区的相对mRNA表达量; （BB）正常区域
-
公开(公告)号：KR1020140004607A
公开(公告)日：2014-01-13
申请号：KR1020130144071
申请日：2013-11-25
Applicant: (주)아모레퍼시픽 , 동국대학교 산학협력단
CPC classification number: C12Q1/6883 , C12Q2600/118 , G01N33/53 , G01N33/68
Abstract: The present invention relates to a method for predicting chloasma formation and a diagnostic kit for chloasma formation and, more specifically, to a method for predicting chloasma formation and a diagnostic kit for chloasma formation, capable of diagnosing the possibility of chloasma formation on the skin by confirming the expression levels of genes which are differently expressed between the chloasma tissue and the normal skin tissue, wherein the diagnostic kit comprises: at least one polynucleotide sequence or its complementary polynucleotide as a probe hybridizing with polynucleotide of the gene sequence; a primer pair of the polynucleotide of the gene sequence; or at least one monoclonal antibody having, as a variable region, an amino acid sequence coded by the gene. According to the present invention, 23 high-expression genes and five low-expression genes, which are specific to a chloasma lesion, are used as a chloasma marker gene, thereby precisely and promptly diagnosing the possibility of chloasma formation on the skin. [Reference numerals] (AA) Relative mRNA expression level of a chloasma region as compared with a normal region; (BBC) Normal region
Abstract translation: 本发明涉及一种用于预测黄褐斑形成的方法和用于黄褐斑形成的诊断试剂盒，更具体地，涉及用于预测黄褐斑形成的方法和用于形成黄褐斑的诊断试剂盒，其能够诊断皮肤上形成黄褐斑的可能性 确认在黄褐斑组织和正常皮肤组织之间不同表达的基因的表达水平，其中所述诊断试剂盒包含：至少一种多核苷酸序列或其互补多核苷酸作为与所述基因序列的多核苷酸杂交的探针; 基因序列的多核苷酸的引物对; 或至少一种具有由该基因编码的氨基酸序列作为可变区的单克隆抗体。 根据本发明，将23个高表达基因和5个低度表达基因（其特异性为黄褐斑病变）用作黄褐斑标记基因，从而准确且及时地诊断皮肤上形成黄褐斑的可能性。 （附图标记）（AA）与正常区域相比，黄褐斑区域的相对mRNA表达水平; （BBC）正常区域
-
公开(公告)号：KR1020090076536A
公开(公告)日：2009-07-13
申请号：KR1020080002544
申请日：2008-01-09
Applicant: 동국대학교 산학협력단
CPC classification number: A61K36/62 , A61K2236/35 , C11B9/00
Abstract: A Nelumbo nuficera extract having treatment effect on dermatitis is provided to promote melanogenesis, enhance tyrosinase activity and prevent and treat pigmentary disorder. A Nelumbo nuficera extract is isolated with n-hexane and have treatment effect on pigmentary disorder including vitiligo, white lentigo, depigmentation after inflammation, and photosensitive skin disorder. The Nelumbo nuficera is petals or stamens of Nelumbo nuficera. A Nelumbo nuficera extract essential oil is obtained by extracting and filtering the Nelumbo nuficera with n-hexane, evaporating at 40~60°C and removing hexane in vacuum. The essential oil comprises palmitic acid, linoleic acie, and their methyl ester. A therapeutic composition of pigmentary skin disorder comprises the essential oil of Nelumbo nuficera extract or palmitic acid methyl ester.
Abstract translation: 提供具有治疗皮肤炎症效果的奈洛卜提取物以促进黑素生成，增强酪氨酸酶活性并预防和治疗色素障碍。 用正己烷分离Nelumbo nuficera提取物，对颜色障碍具有治疗作用，包括白癜风，白色斑疹，炎症后色素沉着和感光性皮肤病。 Nelumbo nuficera是Nelumbo nuficera的花瓣或雄蕊。 通过用正己烷提取和过滤Nelumbo nuficera，在40〜60℃下蒸发，真空除去己烷，得到Nelumbo nuficera萃取精油。 精油包括棕榈酸，亚油酸和它们的甲酯。 色素性皮肤病的治疗组合物包括Nelumbo nuficera提取物或棕榈酸甲酯的精油。
-
19.发明授权봉독을 유효성분으로 포함하는 백반증 치료용 약제학적조성물 및 봉독에 의해 유도되는 색소침착의 억제제를스크리닝하는 방법 有权用于处理包含BEE VENOM的VITILIGO的组合物和用于筛选抑制剂对BEE VENOM诱导的色素的方法
公开(公告)号：KR100844886B1
公开(公告)日：2008-07-09
申请号：KR1020070003866
申请日：2007-01-12
Applicant: 동국대학교 산학협력단
CPC classification number: A61K38/1767 , C07K14/43572 , G01N33/5064 , G01N2500/10
Abstract: A pharmaceutical composition for treating vitiligo comprising bee venom and a method for screening an inhibitor of pigmentation induced by the bee venom are provided to use the bee venom for treating the vitiligo easily and screen the inhibitor of pigmentation induced by the bee venom in a high-throughput manner. A pharmaceutical composition comprises: a pharmaceutically effective amount of bee venom; and a pharmaceutically acceptable carrier. A method for screening an inhibitor of pigmentation induced by the bee venom comprises the steps of: (a) treating a cell with an inhibitor candidate material; (b) treating the cell with the bee venom; and (c) selecting the candidate material which inhibits phosphorylation of Ca^2+ or a cAMP response element binding protein(CREB) or inhibits expression level of a microphthalmia associated transcription factor(MITF). Further, the cell is a melanin cell.
Abstract translation: 提供了一种治疗白癜风的药物组合物，其中包括蜂毒和一种用于筛选由蜂毒引起的色素沉着抑制剂的方法，以便使用蜂毒剂容易地治疗白癜风，并筛选由蜂毒引起的高毒性抑制剂， 吞吐量方式。 药物组合物包含：药用有效量的蜂毒; 和药学上可接受的载体。 用于筛选由蜂毒引起的色素沉着抑制剂的方法包括以下步骤：（a）用抑制剂候选物质处理细胞; （b）用蜂毒处理细胞; 和（c）选择抑制Ca 2+或cAMP反应元件结合蛋白（CREB）磷酸化的候选物质或抑制小耳垢相关转录因子（MITF）的表达水平。 此外，细胞是黑色素细胞。
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.028 seconds)
